RT Journal Article
SR Electronic
T1 Amplitude setting and dopamine response of finger tapping and gait are related in Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.17.21257331
DO 10.1101/2021.05.17.21257331
A1 Syeda, Hafsa Bareen
A1 Glover, Aliyah
A1 Pillai, Lakshmi
A1 Kemp, Aaron S.
A1 Spencer, Horace
A1 Lotia, Mitesh
A1 Larson-Prior, Linda
A1 Virmani, Tuhin
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.17.21257331.abstract
AB Objective Movement amplitude setting is affected early in Parkinson’s disease (PD), clinically manifesting as bradykinesia. Our objective was to determine if amplitude setting of upper limb bimanual movements and bipedal gait are similarly modulated in PD.Methods 27 PD and 24 control participants were enrolled. Participants performed a bimanual anti-phase finger tapping task wearing gloves with joint angular sensors, and an instrumented gait assessment. Motor load was varied by asking participants to perform movements at a normal and fast pace. PD participants were evaluated OFF (PD-OFF) and ON (PD-ON) levodopa.Results PD-OFF participants had shorter tap interval, smaller tap amplitude, and greater tap amplitude variability than controls in the more affected hands (all p<0.05). Tap amplitude and stride length (p=0.030), and tap frequency and gait cadence (p=0.011) were correlated in PD-OFF. Tap frequency and amplitude were also correlated with motor UPDRS (p<0.005) and bradykinesia motor (p<0.05) and ADL (p<0.005) UPDRS subscales. Levodopa improved mean tap amplitude and stride length during fast tapping in PD participants.Conclusion In PD-OFF, mean finger tapping amplitude and gait stride length were correlated and showed similar dopaminergic response.Significance Future studies manipulating upper limb amplitude could help provide greater understanding of the networks responsible for amplitude setting in PD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the UAMS Clinician Scientist Program and the UAMS DEAP Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the UAMS institutional review board (UAMS IRB# 228861).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data sets can be shared at the request of qualified investigators by direct correspondence.